Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
February 4, 2021 is the last day of trading in warrants of series 2019/2021. The subscription period for warrants of series 2019/2021 runs until and including February 8, 2021. Each warrant gives the right to subscribe for one (1) new B share in ADDvise. The subscription price for the warrants is SEK 0.65 per share of series B.
Summarized terms for the warrants of series 2019/2021
Subscription period: January 25, 2021 - February 8, 2021
Size of issue: 43,042,288 warrants of series 2019/2021. Upon full exercise, 43,042,288 shares will be issued and ADDvise receives approximately SEK 28 million before issue costs
Subscription price: SEK 0.65 per series B share
Last day of trading in warrants of series 2019/2021: February 4, 2021
Note that warrants that are not sold no later than February 4, 2021, or alternatively exercised by February 8, 2021, expire worthless. In order for your warrants of series 2019/2021 not to expire, you must subscribe for shares or sell your warrants.
Letter to warrant holders of series 2019/2021 is available at the Company's website, www.addvisegroup.se, and Mangold's website, www.mangold.se. Full terms for the warrants were included as part of the investment memorandum that was published on January 16, 2019. The investment memorandum and full terms and conditions for the warrants are also available at the above websites.How to exercise the warrants
Nominee-registered warrants (custody)
Subscription and payment through the exercise of the warrant shall take place in accordance with instructions from the respective nominee. Please contact your trustee for further information.
Directly registered warrants (VP account):
No issue report or payment instruction will be sent out. Subscription must be made by simultaneous cash payment according to the instructions on the application form. The warrants are then replaced with interim shares (IA) pending registration at Bolagsverket.
The application form with instructions for payment is available on the Company's website, www.addvisegroup.se, and on the issue institute Mangold Fondkommission AB's website, www.mangold.se.
Adviser
Mangold Fondkommission is the financial adviser and Advokatfirman Schjødt is the legal advisor to ADDvise regarding the warrants.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5030 1595
E-mail: emissioner@mangold.se
For further information:
Hanna Myhrman, General Counsel
Tel: +46 709 82 92 23
E-post: hanna.myhrman@addvisegroup.se
About ADDvise
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, ca@mangold.se,is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.